![[ICO]](/icons/blank.gif) | Name | Last modified | Size | Description |
|
![[PARENTDIR]](/icons/back.gif) | Parent Directory | | - | |
![[ ]](/icons/layout.gif) | cyproteron.pdf | 2022-12-01 19:38 | 224K | |
![[ ]](/icons/layout.gif) | vandetanib.pdf | 2022-12-01 19:39 | 249K | |
![[ ]](/icons/layout.gif) | crizotinib.pdf | 2022-12-01 19:39 | 254K | |
![[ ]](/icons/layout.gif) | everolimus.pdf | 2022-09-15 12:14 | 264K | |
![[ ]](/icons/layout.gif) | ceritinib.pdf | 2022-12-01 19:38 | 267K | |
![[ ]](/icons/layout.gif) | acid-zoledronic.pdf | 2022-12-01 19:38 | 270K | |
![[ ]](/icons/layout.gif) | acid-clodronic.pdf | 2022-12-01 19:39 | 272K | |
![[ ]](/icons/layout.gif) | acid-ibandronic.pdf | 2022-12-01 19:38 | 278K | |
![[ ]](/icons/layout.gif) | lapatinib.pdf | 2022-12-01 19:39 | 299K | |
![[ ]](/icons/layout.gif) | interferon-alfa-2a.pdf | 2022-12-01 19:38 | 316K | |
![[ ]](/icons/layout.gif) | trastuzumab-metastatic.pdf | 2022-12-01 19:38 | 320K | |
![[ ]](/icons/layout.gif) | osimertinib.pdf | 2022-09-15 12:14 | 325K | |
![[ ]](/icons/layout.gif) | ipilimumab.pdf | 2022-12-01 19:39 | 327K | |
![[ ]](/icons/layout.gif) | ramucirumab.pdf | 2022-09-15 12:14 | 327K | |
![[ ]](/icons/layout.gif) | everolimus-afinitor.pdf | 2022-12-01 19:39 | 328K | |
![[ ]](/icons/layout.gif) | ribociclib.pdf | 2022-12-01 19:38 | 330K | |
![[ ]](/icons/layout.gif) | axitinib.pdf | 2022-12-01 19:39 | 331K | |
![[ ]](/icons/layout.gif) | aflibercept.pdf | 2022-12-01 19:38 | 331K | |
![[ ]](/icons/layout.gif) | trastuzumab-non-metastatic.pdf | 2022-12-01 19:38 | 332K | |
![[ ]](/icons/layout.gif) | erlotinib.pdf | 2022-12-01 19:38 | 332K | |
![[ ]](/icons/layout.gif) | panitumumab.pdf | 2023-02-10 09:22 | 332K | |
![[ ]](/icons/layout.gif) | palbociclib.pdf | 2022-12-01 19:38 | 332K | |
![[ ]](/icons/layout.gif) | trastuzumab-emtansina.pdf | 2022-12-01 19:39 | 333K | |
![[ ]](/icons/layout.gif) | afatinib.pdf | 2022-12-01 19:39 | 334K | |
![[ ]](/icons/layout.gif) | trabectedina.pdf | 2022-12-01 19:39 | 336K | |
![[ ]](/icons/layout.gif) | imatinib.pdf | 2022-12-01 19:38 | 337K | |
![[ ]](/icons/layout.gif) | cabazitaxel.pdf | 2022-12-01 19:39 | 338K | |
![[ ]](/icons/layout.gif) | epoetine.pdf | 2022-12-01 19:38 | 339K | |
![[ ]](/icons/layout.gif) | irinotecan-onyvide.pdf | 2022-12-01 19:38 | 341K | |
![[ ]](/icons/layout.gif) | fulvestrant.pdf | 2022-12-01 19:38 | 341K | |
![[ ]](/icons/layout.gif) | dabrafenib.pdf | 2022-12-01 19:38 | 341K | |
![[ ]](/icons/layout.gif) | abemaciclib.pdf | 2022-12-01 19:38 | 344K | |
![[ ]](/icons/layout.gif) | lonsurf.pdf | 2022-12-01 19:39 | 344K | |
![[ ]](/icons/layout.gif) | pemetrexed.pdf | 2022-12-01 19:38 | 347K | |
![[ ]](/icons/layout.gif) | sunitinib.pdf | 2022-12-01 19:38 | 349K | |
![[ ]](/icons/layout.gif) | enzalutamida.pdf | 2022-12-01 19:38 | 351K | |
![[ ]](/icons/layout.gif) | TEV.pdf | 2022-12-01 19:39 | 352K | |
![[ ]](/icons/layout.gif) | abiraterona.pdf | 2022-12-01 19:38 | 355K | |
![[ ]](/icons/layout.gif) | alectinib.pdf | 2022-12-01 19:38 | 355K | |
![[ ]](/icons/layout.gif) | durere-cronica-cancer.pdf | 2022-12-01 19:38 | 358K | |
![[ ]](/icons/layout.gif) | goserelina.pdf | 2022-12-01 19:38 | 358K | |
![[ ]](/icons/layout.gif) | cetuximab.pdf | 2022-12-01 19:38 | 359K | |
![[ ]](/icons/layout.gif) | sorafenib.pdf | 2022-12-01 19:38 | 362K | |
![[ ]](/icons/layout.gif) | regoafenib.pdf | 2022-12-01 19:39 | 362K | |
![[ ]](/icons/layout.gif) | dabrafenib-trametinib.pdf | 2022-12-01 19:38 | 363K | |
![[ ]](/icons/layout.gif) | pazopanib.pdf | 2022-12-01 19:39 | 367K | |
![[ ]](/icons/layout.gif) | vemurafenib.pdf | 2022-12-01 19:39 | 368K | |
![[ ]](/icons/layout.gif) | tumori-neuroendocrine.pdf | 2022-12-01 19:39 | 370K | |
![[ ]](/icons/layout.gif) | avelumab.pdf | 2022-09-15 12:14 | 372K | |
![[ ]](/icons/layout.gif) | pegfilgrastim.pdf | 2022-12-01 19:38 | 378K | |
![[ ]](/icons/layout.gif) | leuprorelina.pdf | 2022-12-01 19:38 | 384K | |
![[ ]](/icons/layout.gif) | gefitinib.pdf | 2022-12-01 19:39 | 384K | |
![[ ]](/icons/layout.gif) | antiemetice.pdf | 2022-12-01 19:39 | 388K | |
![[ ]](/icons/layout.gif) | bevacizumab.pdf | 2022-12-01 19:38 | 411K | |
![[ ]](/icons/layout.gif) | cabozantinib.pdf | 2022-09-15 12:14 | 416K | |
![[ ]](/icons/layout.gif) | olaparib.pdf | 2022-09-15 12:14 | 418K | |
![[ ]](/icons/layout.gif) | tivozanib.pdf | 2022-09-15 12:14 | 474K | |
![[ ]](/icons/layout.gif) | pertuzumab-trastuzumab.pdf | 2022-09-15 12:14 | 483K | |
![[ ]](/icons/layout.gif) | nivo-ipi.pdf | 2022-12-01 19:39 | 489K | |
![[ ]](/icons/layout.gif) | pertuzuzumab.pdf | 2022-12-01 19:39 | 529K | |
![[ ]](/icons/layout.gif) | apalutamida.pdf | 2022-12-01 19:38 | 536K | |
![[ ]](/icons/layout.gif) | atezolizumab.pdf | 2022-09-15 12:14 | 557K | |
![[ ]](/icons/layout.gif) | cemiplimab.pdf | 2022-12-01 19:39 | 581K | |
![[ ]](/icons/layout.gif) | durvalumab.pdf | 2022-12-01 19:39 | 600K | |
![[ ]](/icons/layout.gif) | nivolumab.pdf | 2022-12-01 19:39 | 611K | |
![[ ]](/icons/layout.gif) | pembrolizumab.pdf | 2022-12-01 19:39 | 653K | |
|